Physician profile
Janice M Rivera
NPI 1326604752
$2,665.32
in general payments reported to CMS, 2019-2025
26 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.13 · 2024: $565 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.04 | 2024-2025 | |
| Pfizer INC. | $308.96 | 2024-2025 | |
| Lundbeck LLC | $212.14 | 2024-2025 | Vyepti, Rexulti |
| Eisai INC. | $165.77 | 2024-2025 | |
| Ucb, INC. | $165.32 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Argenx US, INC. | $149.91 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $131.24 | 2024-2025 | Ponvory |
| Lilly USA, LLC | $116.45 | 2024-2025 | Kisunla, Amyvid |
| Catalyst Pharmaceuticals, INC. | $93.82 | 2024-2025 | |
| Tg Therapeutics, INC. | $87.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $86.08 | 2024-2025 | |
| Amgen INC. | $77.80 | 2024-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $59.56 | 2024-2025 | Crexont, Ongentys |
| Merz Pharmaceuticals, LLC | $55.15 | 2025 | Inbrija, Xeomin, Ampyra |
| Neurelis, INC. | $54.43 | 2024-2025 | Valtoco |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $51.47 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $49.72 | 2025 | |
| Jazz Pharmaceuticals INC. | $37.34 | 2023-2024 | |
| Nevro Corp. | $28.20 | 2024 | Senza |
| Genentech USA, INC. | $27.21 | 2024 | Ocrevus, Enspryng |
| Boston Scientific Corporation | $24.67 | 2025 | General - Dbs |
| Biogen, INC. | $21.40 | 2024 | Vumerity |
| Otsuka America Pharmaceutical, INC. | $15.58 | 2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $15.22 | 2025 | Purified Cortrophin Gel |
| Aucta Pharmaceuticals, INC. | $15.21 | 2025 | Motpoly Xr |
| C2n Diagnostics, LLC | $15.12 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.